Allworth Financial LP Biomarin Pharmaceutical Inc Transaction History

Allworth Financial LP

$15.5 Billion
Q2 2024

A detailed history of Allworth Financial LP transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Allworth Financial LP holds 1,968 shares of BMRN stock, worth $138,901. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,968

Previous 1,964 0.2%

Holding current value

$138,901

Previous $171,000 5.26%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 23, 2024	BUY	$74.43 - $92.22 $297 - $368	4 Added 0.2%	1,968 $162,000
Q1 2024 Apr 25, 2024	BUY	$83.81 - $99.0 $113,981 - $134,640	1,360 Added 225.17%	1,964 $171,000
Q4 2023 Jan 24, 2024	BUY	$76.22 - $98.51 $16,311 - $21,081	214 Added 54.87%	604 $58,000
Q3 2023 Oct 31, 2023	BUY	$85.07 - $94.48 $3,743 - $4,157	44 Added 12.72%	390 $34,000
Q2 2023 Jul 18, 2023	SELL	$86.68 - $100.3 $866 - $1,003	-10 Reduced 2.81%	346 $29,000
Q1 2023 Apr 18, 2023	BUY	$87.74 - $117.27 $11,406 - $15,245	130 Added 57.52%	356 $34,000
Q4 2022 Jan 13, 2023	BUY	$80.93 - $108.63 $2,185 - $2,933	27 Added 13.57%	226 $0
Q3 2022 Oct 18, 2022	BUY	$82.16 - $96.94 $3,204 - $3,780	39 Added 24.38%	199 $17,000
Q2 2022 Jul 13, 2022	SELL	$71.48 - $86.85 $7,290 - $8,858	-102 Reduced 38.93%	160 $13,000
Q3 2021 Nov 02, 2021	BUY	$74.77 - $85.47 $9,421 - $10,769	126 Added 92.65%	262 $20,000
Q2 2021 Aug 02, 2021	SELL	$75.51 - $84.79 $1,887 - $2,119	-25 Reduced 15.53%	136 $11,000
Q1 2021 Apr 29, 2021	BUY	$74.73 - $90.69 $1,569 - $1,904	21 Added 15.0%	161 $12,000
Q3 2020 Nov 03, 2020	BUY	$71.87 - $131.03 $1,796 - $3,275	25 Added 21.74%	140 $11,000
Q4 2019 Jan 16, 2020	BUY	$64.27 - $86.37 $7,391 - $9,932	115 New	115 $10,000

Others Institutions Holding BMRN

# of Institutions

632

Shares Held

185M

Call Options Held

1.63M

Put Options Held

1.2M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Allworth Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Allworth Financial LP with notifications on news.

Account

Allworth Financial LP Biomarin Pharmaceutical Inc Transaction History